NCT05281783View on ClinicalTrials.gov

RFA for Treatment of Intermediate Stage HCC

NACompletedINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

October 1, 2018

Primary Completion Date

June 1, 2021

Study Completion Date

August 1, 2021

Conditions
Hepatocellular Carcinoma
Interventions
DEVICE

percutaneous radiofrequency ablation (RFA)

We aim to evaluate the percutaneous radiofrequency ablation (RFA) efficacy as monotherapy in intermediate versus early-stage hepatocellular carcinoma (HCC).

Trial Locations (1)

Unknown

Interventional Ultrasonography Unit, Tropical Medicine Department, Beni-Suef University Hospitals, Banī Suwayf

All Listed Sponsors
lead

Benha University

OTHER

collaborator

Beni-Suef University

OTHER

NCT05281783 - RFA for Treatment of Intermediate Stage HCC | Biotech Hunter | Biotech Hunter